NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
BioNTech SE BNTX
9 fiscal years on record · EUR · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in BioNTech SE's annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.
Growth
EUR 2.9B
Revenue, FY2025 · full 9-year series below
Revenue €B
Net income €B
FY2025 · Revenue 2.9 · Net income -1.1
Compound annual growth
Revenue compounded at +42.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−40 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -49.0% · Net -39.6%
ROE
FY2020 · ROE 3.1%
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 2.9 | 2.8 | 3.8 | 17.3 | 19.0 | 0.5 | 0.1 | 0.1 | 0.1 |
| Operating income €B | −1.4 | −1.3 | 0.7 | 12.6 | 15.3 | −0.1 | −0.2 | −0.1 | −0.1 |
| EBITDA €B | −1.3 | −1.3 | 0.7 | · | · | · | · | · | · |
| Income tax €B | 0.1 | −0.0 | 0.3 | 3.5 | 4.8 | −0.2 | −0.0 | 0.0 | 0.0 |
| Net income €B | −1.1 | −0.7 | 0.9 | 9.4 | 10.3 | 0.0 | −0.2 | −0.0 | −0.1 |
| Free cash flow €B | 0.3 | −0.1 | 5.1 | 13.2 | 0.8 | −0.1 | −0.2 | −0.1 | −0.1 |
| EPS, diluted € | −4.70 | −2.77 | 3.83 | 37.77 | 39.63 | 0.06 | −0.85 | · | · |
| Dividend / sh € | · | · | · | · | · | · | · | · | · |
| Payout % | · | −0 | 0 | 5 | 0 | 0 | · | · | · |
| ROE % | · | · | · | · | · | 3.1 | −47.2 | −18.0 | · |
| Shares out B | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 35 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 54 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code 2M
Fiscal year endsDecember 31
Data on record since2017